Brief: Sab Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating Sab-185 Met Criteria For Advancement To Phase 3 In Nih Activ-2 Trial For Treatment Of Covid-19
24/01/2022 12:53
Jan 24 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS REPORTS POSITIVE PHASE 2 VIROLOGY DATA
DEMONSTRATING SAB-185 MET CRITERIA FOR ADVANCEMENT TO PHASE 3 IN
NIH ACTIV-2 TRIAL FOR TREATMENT OF COVID-19
* SAB BIOTHERAPEUTICS INC - SAB-185 WAS SAFE AND
WELL-TOLERATED AT
BOTH DOSES TESTED IN PHASE 2
Source text for Eikon: ID:nGNX3zdhy6
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies